The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients

BACKGROUND: Tacrolimus (TAC) is the mainstay of immunosuppressive regimen for kidney transplantations. Its clinical use is complex due to high inter‐individual variations which can be partially attributed to genetic variations at the metabolizing enzymes CYP3A4 and CYP3A5. Two single nucleotide poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanas, Hanaa, Kamel, Mai Hamed, William, Emad Adel, Fayad, Tarek, Abdelfattah, Mohamed Essmat, Elbadawy, Hossein Mostafa, Mikhael, Emily Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681408/
https://www.ncbi.nlm.nih.gov/pubmed/37789683
http://dx.doi.org/10.1002/jcla.24969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681408/
https://www.ncbi.nlm.nih.gov/pubmed/37789683
http://dx.doi.org/10.1002/jcla.24969

Ejemplares similares